10777 completed, 2918 recruiting, 2788 unknown, 2423 terminated. 7544 Phase 2, 5383 Phase 1, 2921 Not applicable, 2640 Phase 3, 937 Phase 4.
Follow Hematologic Diseases: new trials by email Literature Review of Hematologic Diseases trials Research Report on Hematologic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sonrotoclax in Combination With Azacitidine for Previously Untreated Higher-risk Myelodysplastic Syndromes Each treatment cycle is 28-days. Azacitidine 75 mg/m² is administered subcutaneously or intravenously on Days 1-7 of each cycle. Sonrotoclax is orally administered once daily on Days 1-14 within each - MDS (Myelodysplastic Syndrome) | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 10 | 2028-09-01 | 2026-11-12 |
| A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia Blinatumomab, HyperCVAD - Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia | Phase 3 | Not yet recruiting | Amgen | 560 | 2028-06-30 | 2026-09-15 |
| Safety and Efficacy of KL003 Cell Injection in Severe Sickle Cell Disease KL003 Cell Injection - Sickle Cell Disease | Not applicable | Suspended | Institute of Hematology & Blood Diseases Hospital, China | 3 | 2028-03-01 | 2026-11-05 |
| Pyronaridine in Acute Myeloid Leukemia (AML) Pyronaridine Tetraphosphate - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Suspended | Armaceutica, Inc. | 200 | 2028-02-21 | 2026-10-19 |
| Effect of Ginger on Heavy Menstrual Bleeding in Women With Coagulation Disorders Ginger, Placebo - Women With Coagulation Disorders | Early Phase 1 | Not yet recruiting | University of Valladolid | 74 | 2028-02-01 | 2026-05-19 |
| MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma Oncology-Embedded Cardiovascular Risk Assessment Pathway, Primary Care Provider-Directed Cardiovascular Risk Assessment Pathway - Multiple Myeloma, Heart Disease Risk Factors | Not applicable | Not yet recruiting | University of Vermont Medical Center | 33 | 2028-02-01 | 2026-08-25 |
| Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion, Gemtuzumab Ozogamicin - Relapsed/Refractory Acute Myeloid Leukemia (AML) | Phase 1 | Not yet recruiting | German Cancer Research Center | 12 | 2028-01-01 | 2025-03-14 |
| OPTIMAL LEAP: Optimizing Dihydroartemisinin-Piperaquine IPTsc Intervals to Advance Learning, Executive Function, Attendance, and Antimalarial Resistance Surveillance in Kenyan Schoolchildren Monthly DP, Quarterly DP - Malaria, Asymptomatic Malaria | Phase 3 | Not yet recruiting | Indiana University | 1500 | 2028-01-01 | 2026-09-01 |
| Methadone as an Alternative Treatment for Children Underdoing HSCT PCA plus methadone (Experimental), PCA Alone (SOC) - Leukemia, Aplastic Anemia | Phase 3 | Suspended | University of Texas Southwestern Medical Center | 60 | 2028-01-01 | 2025-10-23 |
| Prenatal Transplantation for Fetuses With Fanconi Anemia IUHSCT for FA-affected fetuses - Fanconi Anemia, Anemia, Hypoplastic, Congenital | Phase 1 / Phase 2 | Not yet recruiting | Agnieszka Czechowicz | 12 | 2028-01-01 | 2026-06-16 |
| A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML) Cytarabine, Oral Cladribine - Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 58 | 2027-12-01 | 2026-08-25 |
| Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma YKST02 - Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 2 | Not yet recruiting | Excyte Biopharma Ltd | 64 | 2027-12-01 | 2026-11-06 |
| Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy NM8074 - aHUS - Atypical Hemolytic Uremic Syndrome | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 12 | 2027-11-01 | 2026-04-13 |
| Self-administered Acupressure in Patients With Sickle Cell Disease Verum Acupressure (using AcuWand), Sham Acupressure (using AcuWand) - Sickle Cell Disease (SCD) | Not applicable | Not yet recruiting | University of Cincinnati | 300 | 2027-10-01 | 2026-10-15 |
| The Feasibility and Effects of Exercise on Patients Suffering From Multiple Myeloma Individual Exercise, Group Exercise - Multiple Myeloma | Not applicable | Suspended | Medical University of Vienna | 45 | 2027-09-01 | 2026-10-09 |
| Development of a Provider-Focused Intervention to Improve Health Outcomes in Pediatric Sickle Cell Disease Individuation and Perspective-Taking (IPT), pediatric SCD pain management education session - Sickle Cell Disease, Sickle Cell Anemia in Children | Not applicable | Not yet recruiting | Connecticut Children's Medical Center | 30 | 2027-09-01 | 2026-04-29 |
| Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | City of Hope Medical Center | 44 | 2027-08-04 | 2026-09-10 |
| Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic Coagulopathy • Sivelestat intravenous infusion, NaCl intravenous infusion - Septic Shock, Coagulopathy | Phase 2 | Not yet recruiting | University Hospital, Strasbourg, France | 120 | 2027-08-01 | 2026-08-20 |
| Conditioning Regimen Containing Low-Dose ATG for the Treatment of AA Receiving sUCBT Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®) - Aplastic Anaemia | Phase 2 | Not yet recruiting | Anhui Provincial Hospital | 59 | 2027-08-01 | 2026-10-21 |
| Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/ βC Genotype Exa-cel - Sickle Cell Disease | Phase 3 | Withdrawn | Vertex Pharmaceuticals Incorporated | 2027-07-31 | 2026-03-25 |
Showing 20 of 22314. Sign in to see all of them.
Multiple Myeloma (3675) · Leukemia, Myeloid, Acute (3593) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2522) · Leukemia (2382) · Leukemia, Lymphocytic, Chronic, B-Cell (2018) · Myelodysplastic Syndromes (1970) · Anemia (1670) · Hematologic Neoplasms (1444) · Lymphoma (1376) · Lymphoma, Non-Hodgkin (1210) · Anemia, Sickle Cell (1122) · Recurrence (978) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (878) · Neoplasms (870) · Lymphoma, Follicular (814)
Hemic and Lymphatic Diseases (22309) · Neoplasms (12862) · Neoplasms by Histologic Type (12182) · Immune System Diseases (9868) · Immunoproliferative Disorders (8344) · Lymphoproliferative Disorders (8211) · Pathological Conditions, Signs and Symptoms (6794) · Leukemia (6416) · Hemorrhagic Disorders (6356) · Pathologic Processes (6252) · Lymphatic Diseases (5520) · Cardiovascular Diseases (5134) · Vascular Diseases (5029) · Disease Attributes (4606)
Cyclophosphamide (1286) · Dexamethasone (1187) · Cytarabine (938) · fludarabine (706) · Lenalidomide (654) · Bortezomib (585) · Rituximab (579) · Azacitidine (568) · fludarabine phosphate (561) · venetoclax (546) · Methotrexate (450) · Melphalan (440) · Filgrastim (436) · Busulfan (401) · Calcium Dobesilate (364)
M.D. Anderson Cancer Center (666) · National Cancer Institute (NCI) (595) · Novartis Pharmaceuticals (350) · Fred Hutchinson Cancer Center (251) · Institute of Hematology & Blood Diseases Hospital, China (250) · Memorial Sloan Kettering Cancer Center (232) · Assistance Publique - Hôpitaux de Paris (216) · National Heart, Lung, and Blood Institute (NHLBI) (205) · Mayo Clinic (201) · Hoffmann-La Roche (199) · Celgene (186) · Amgen (177) · St. Jude Children's Research Hospital (175) · Pfizer (172) · Children's Oncology Group (164)
United States (10667) · China (2499) · France (2419) · Italy (1832) · Germany (1760) · United Kingdom (1545) · Spain (1519) · Canada (1513) · Australia (1009) · Netherlands (781) · Belgium (778) · South Korea (756) · Poland (747) · Japan (672) · Israel (641)
PMID 36005278, PMID 36791280, PMID 41671463, PMID 32499241, PMID 41114449, PMID 34932836, PMID 34515338, PMID 35622074, PMID 26965694, PMID 37975597, PMID 33783815, PMID 34398557, PMID 36240296, PMID 38780066, PMID 33394722, PMID 19005182, PMID 24383844, PMID 25527568, PMID 33242441, PMID 33357481, PMID 40750723, PMID 23524640, PMID 29674506, PMID 31221778, PMID 31375516, PMID 34724566, PMID 35235189, PMID 35244208, PMID 35829925, PMID 36064577, PMID 36184192, PMID 37022569, PMID 37254256, PMID 38620092, PMID 22689675, PMID 23065508, PMID 23620574, PMID 28835440, PMID 29419434, PMID 29958797, PMID 30885996, PMID 30957581, PMID 34922648, PMID 37192741, PMID 38775255, PMID 40396505, PMID 42013378, PMID 19846889, PMID 26196195, PMID 27400247
2023 (208), 2016 (113), 2018 (110), 2017 (108), 2014 (106), P30CA015704 (102), 2019 (98), 2015 (96), P30CA033572 (93), 2025 (81), P30CA015083 (81), 2009 (75), 2008 (63), U10CA032102 (61), U10CA180820 (58)